This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:
Trump Media ($DJT) Jumps on Fusion Energy Merger Deal
Trump Media & Technology Group ($DJT), the company behind Truth Social and other digital platforms, announced a major move into clean energy after agreeing to merge with TAE Technologies, a private U.S. fusion power company, in an all-stock transaction valued at more than $6 billion.
According to the companies, the deal will create one of the world’s first publicly traded fusion energy companies, with Trump Media and TAE shareholders each owning about 50% of the combined business. The combined company plans to select a site and begin construction of its first utility-scale fusion power plant in 2026, targeting an initial capacity of 50 megawatts, with much larger plants planned later.
Trump Media said it will contribute significant capital to help accelerate TAE’s path to commercialization, including up to $200 million at signing and another $100 million tied to regulatory filings. TAE brings more than 25 years of research, five operating fusion reactors, and backing from major investors such as Google and Chevron. The company says its technology avoids many of the risks associated with traditional nuclear power, such as radioactive waste or meltdown concerns.
Management framed the deal as a long-term bet on energy security and powering future AI infrastructure, with the combined company aiming to position fusion as a reliable, carbon-free electricity source for data centers, industry, and national infrastructure.
The transaction is expected to close in mid-2026, pending shareholder and regulatory approvals.
Stock Price Reaction
$DJT shares surged more than 40% following the announcement.
Ramaco ($METC) Authorizes $100M Share Buyback
Ramaco Resources ($METC), a U.S.-based producer of metallurgical coal used in steelmaking, announced that its board has approved a share repurchase program of up to $100 million for its Class A common stock.
According to the company, the buyback will run for up to 24 months and gives Ramaco flexibility to repurchase shares in the open market or through pre-arranged trading plans. The board also approved the use of formal trading plans to help carry out the program in line with market rules.
Management said the decision reflects confidence in Ramaco’s financial position following the completion of more than $600 million in capital raises during the second half of 2025. The company described the buyback as another way to return capital to shareholders while continuing to invest in its operations.
The authorization does not require Ramaco to repurchase a specific number of shares and can be adjusted, paused, or ended depending on market conditions and capital needs.
Stock Price Reaction
$METC shares jumped about 8% following the announcement, as investors reacted positively to the buyback authorization and the signal of balance sheet strength.
Dynavax ($DVAX) to Be Acquired by Sanofi in $2.2B Deal
Dynavax ($DVAX) is a U.S.-based vaccine company best known for HEPLISAV-B, an adult hepatitis B vaccine already sold in the U.S., and a developing shingles vaccine candidate. The company announced that it has agreed to be acquired by Sanofi in an all-cash deal that values Dynavax at about $2.2 billion.
Under the agreement, Sanofi will acquire all outstanding Dynavax shares for $15.50 per share in cash, according to the company. The deal brings HEPLISAV-B into Sanofi’s global vaccine portfolio and also adds Dynavax’s early-stage shingles vaccine candidate (Z-1018), which is currently in Phase 1/2 testing.
HEPLISAV-B stands out because it requires just two doses given one month apart, compared with traditional hepatitis B vaccines that typically require three doses over six months. According to the company, this shorter schedule helps patients reach protection faster, which has supported adoption in the U.S. adult market. Sanofi plans to use its global scale and commercial reach to expand the vaccine’s impact.
Dynavax’s board unanimously approved the transaction. The deal is expected to close in the first quarter of 2026, subject to standard regulatory approvals and shareholder tender conditions. Sanofi said it plans to fund the acquisition using existing cash and does not expect the deal to change its 2025 financial guidance.
Stock Price Reaction
Dynavax shares surged more than 30% following the announcement, reflecting the cash buyout premium and investor confidence that the deal will close as planned.
This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.
